CliffBio
small molecule

TRELSTAR

TRIPTORELIN PAMOATE

Loss of exclusivity—loss of exclusivity
CompanyVerity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRELSTAR
Active ingredientTRIPTORELIN PAMOATE
StrengthEQ 3.75MG BASE/VIAL
Dosage formINJECTABLE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJune 2000
Marketing statusRX

More from Verity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

TRELSTAR patent cliff — loss of exclusivity — | CliffBio